Acadia Pharmaceuticals | ACAD - Zinsaufwendungen Für Schuld

Aktienkurs
21.96
Täglich Wechseln
-0.15 -0.68%
Monatlich
-0.23%
Jährlich
49.08%
Q2 Prognose
21.49




Zinsaufwendungen Für Schuld Veränderung Datum
Acadia Pharmaceuticals USD 0 4.12M 2024-09
ALKERMES USD 12.28M 7.63M 2025-12
Alnylam Pharmaceuticals USD 129.34M 84.94M 2025-12
Biogen USD 72.6M 12.6M 2025-06
BioMarin Pharmaceutical USD 2.78M 199K 2025-12
Bristol-Myers Squibb USD 432M 48M 2025-12
Cara Therapeutics 39.02M 4.73M 2025-09
Corcept Therapeutics USD 823.61M 21.88M 2025-09
Cytokinetics USD 30.33M 4.01M 2025-12
Eisai JPY 1.43B 12M 2025-12
Eli Lilly USD 114.7M 134.3M 2025-09
Incyte USD 582K 10K 2025-12
J&J USD 43M 25M 2026-03
Moderna USD 12.14B 12.13B 2025-09
Neurocrine Biosciences USD 1.1M 0 2024-03
Pfizer USD 711M 59M 2025-12
Prothena USD 2.62M 350M 2025-12
PTC Therapeutics USD 50.58M 2.59B 2025-12
Sarepta Therapeutics USD 7.56M 2.33M 2025-09
Ultragenyx Pharmaceutical USD 19M 4.85M 2025-12
Vanda Pharmaceuticals 601.14M 23.61M 2025-09
Vertex Pharmaceuticals USD 3.3M 0 2025-12